Neurolief has announced the approval of its neuromodulation device, Relivion®, by the Japanese Ministry of Health, Labor and Welfare (MHLW), making Relivion® the first neuromodulation device approved in Japan for home use in the acute treatment of migraine.
Relivion® is a novel, non-invasive, multi-channel brain neuromodulation technology. It features simultaneous stimulation of the occipital and trigeminal nerve branches in the head, effectively modulating brain networks associated with debilitating migraine headaches. The system is complemented by a state-of-the-art mobile patient app and physician interface with cloud-enabled data tracking capabilities, enabling seamless AI integration and remote patient monitoring.
Marketing efforts for Relivion® will be led by Sawai Pharmaceutical, which has entered into an exclusive partnership agreement with Neurolief for the development and commercialization of Relivion® for migraine and depression indications in Japan.